A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 vs Capecitabine (Xeloda) in Patients With Colorectal Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens.

Trial Profile

A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 vs Capecitabine (Xeloda) in Patients With Colorectal Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Capecitabine; Selumetinib
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2010 Primary endpoint 'Disease progression rate' has not been met.
    • 02 Feb 2010 Results published in Investigational New Drugs.
    • 15 May 2009 Actual end date changed from Jun 2007 to Jul 2008 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top